These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26516934)

  • 21. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Therapy and Immunotherapy for Lung Cancer.
    Naylor EC; Desani JK; Chung PK
    Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates on immunotherapy in non-small cell lung cancer.
    Shimanovsky A; Dasanu CA
    Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Dec; 139(12):1477-8. PubMed ID: 26619015
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemistry in the era of personalised medicine.
    McCourt CM; Boyle D; James J; Salto-Tellez M
    J Clin Pathol; 2013 Jan; 66(1):58-61. PubMed ID: 23002284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenic targets in non-small cell lung cancer: more is more.
    Gnjatic S
    Clin Cancer Res; 2005 Aug; 11(15):5331-2. PubMed ID: 16061843
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
    Rolfo C; Sortino G; Smits E; Passiglia F; Bronte G; Castiglia M; Russo A; Santos ES; Janssens A; Pauwels P; Raez L
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1173-87. PubMed ID: 25148289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
    Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
    Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
    Klein O; Kee D; Markman B; Carlino MS; Underhill C; Palmer J; Power D; Cebon J; Behren A
    Cancer Cell; 2021 May; 39(5):592-593. PubMed ID: 33930312
    [No Abstract]   [Full Text] [Related]  

  • 36. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
    Kakimi K; Nakajima J; Wada H
    Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
    Gianni L; Grasselli G
    Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
    [No Abstract]   [Full Text] [Related]  

  • 40. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
    Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
    Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.